Kopecky KJ - Search Results

1

Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.

Slavik M, Kopecky KJ, Sondak V, Craig JB, Samson MK. Slavik M, et al. Among authors: kopecky kj. Invest New Drugs. 1993 May-Aug;11(2-3):223-6. doi: 10.1007/BF00874160. Invest New Drugs. 1993. PMID: 8262736 Free article. Clinical Trial.

2

Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.

Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM. Kish JA, et al. Invest New Drugs. 1991 Feb;9(1):105-8. doi: 10.1007/BF00194559. Invest New Drugs. 1991. PMID: 1709151 Clinical Trial.

3

Phase II evaluation of spirogermanium in malignant melanoma: a Southwest Oncology Group Study.

Goodwin JW, Kopecky K, Slavik M, Tranum BL, Balcerzak SP, Fletcher WS, Costanzi JJ. Goodwin JW, et al. Cancer Treat Rep. 1987 Oct;71(10):985-6. Cancer Treat Rep. 1987. PMID: 3652061 No abstract available.

4

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR. Sondak VK, et al. Among authors: kopecky kj. Anticancer Drugs. 1994 Apr;5(2):147-50. Anticancer Drugs. 1994. PMID: 8049497 Clinical Trial.

5

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.

Whitehead RP, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, Hersh EM, Rinehart JJ. Whitehead RP, et al. Among authors: kopecky kj. J Natl Cancer Inst. 1991 Sep 4;83(17):1250-2. doi: 10.1093/jnci/83.17.1250. J Natl Cancer Inst. 1991. PMID: 1870152 Clinical Trial. No abstract available.

6

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Meyskens FL Jr, et al. Among authors: kopecky kj. J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3. doi: 10.1093/jnci/87.22.1710. J Natl Cancer Inst. 1995. PMID: 7473820 Clinical Trial. No abstract available.

7

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.

Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, Coltman C. Meyskens FL Jr, et al. J Natl Cancer Inst. 1990 Jun 20;82(12):1071. doi: 10.1093/jnci/82.12.1071-a. J Natl Cancer Inst. 1990. PMID: 2112201 Clinical Trial. No abstract available.

8

High-dose cisplatin in disseminated melanoma: a comparison of two schedules.

Mortimer JE, Schulman S, MacDonald JS, Kopecky K, Goodman G. Mortimer JE, et al. Cancer Chemother Pharmacol. 1990;25(5):373-6. doi: 10.1007/BF00686241. Cancer Chemother Pharmacol. 1990. PMID: 2306798

9

Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.

Head DR, Kopecky KJ, Willman C, Appelbaum FR. Head DR, et al. Among authors: kopecky kj. Leukemia. 1994;8 Suppl 2:S38-41. Leukemia. 1994. PMID: 7815835 Clinical Trial.

10

Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.

Bigelow CL, Kopecky K, Files JC, Head D, Lipschitz DA, Grever M, Appelbaum FR. Bigelow CL, et al. Am J Hematol. 1995 Apr;48(4):228-32. doi: 10.1002/ajh.2830480404. Am J Hematol. 1995. PMID: 7717369 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters